

## FOI Request re Number of Patients Treated

Please detail the number of Oncology<sup>1</sup> patients treated<sup>2</sup> by your Trust with the stated therapies, during the time period **January 2019 to June 2019** inclusive.

	Total Number of Patients Treated:					
	Total Number of Patients Treated	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)						
Nivolumab (Opdivo)						
Ipilimumab (Yervoy)						
Dabrafenib (Tafinlar)	7	7				
Cabozantinib (Cabometyx)						
Sunitinib (Sutent)						
Pazopanib (Votrient)						
Axitinib (Inlyta)						
Atezolizumab (Tecentriq)						
Sorafenib (Nexavar)						
Tivozanib (Fotivda)						
Lenvatinib (Lenvima)						
Cetuximab (Erbix)						
Everolimus (Afinitor)						
Vemurafenib (Zelboraf)						

1

Cancer Type	Diagnoses Codes (ICD10)
Head & Neck	C00-C14; C30-C32
Adjuvant Melanoma	C43 (treatment as additional treatment following primary)
Metastatic Melanoma	C43 plus C77, C78, C79
NSCLC	C34
RCC	C64

<sup>2</sup> Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).